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Abstract
Background: Hepatitis C virus (HCV) is one of the major public health problems both in developed and developing
countries. Prison represents a high-risk environment for prisoners, in that it is characterized by high-risk behaviors
such as injecting drug use (IDU), tattooing, unprotected sexual intercourses, or sharing syringes. The aim of this
study was to quantitatively evaluate the prevalence of HCV among Iranian prisoners conducting a systematic review
and meta-analysis.
Methods: We searched different scholarly databases including Embase, PubMed/MEDLINE, ISI/Web of Sciences, the
Cochrane library, Scopus, CINAHL, and PsycINFO as well as Iranian bibliographic thesauri (namely, Barakatns, MagIran,
and SID) up to December 2017. The Newcastle Ottawa Scale (NOS) was used to assess the quality of the studies
included. HCV prevalence rate with its 95% confidence interval (CI) was estimated using the DerSimonian-Laird
random-effects model, with Freeman-Tukey double arcsine transformation. Egger’s regression test was used to
evaluate publication bias.
Results: Finally, 17 articles were selected based on inclusion and exclusion criteria. Overall, 18,693 prisoners were
tested. Based on the random-effects model, the prevalence of HCV among Iranian prisoners was 28% (CI 95% 21–
36) with heterogeneity of I2 = 99.3% (p = 0.00). All studies used an ELISA test for the evaluation of HCV antibodies.
The findings of this study showed that the highest prevalence rate (53%) was among prisoners who inject drugs.
Conclusion: The findings of our study showed that the prevalence of HCV among Iranian prisoners is dramatically high.
Managing this issue in Iran’s prisons requires careful attention to the availability of health facilities and instruments, such
as screening, and harm reduction policies, such as giving sterile syringes and needles to prisoners. An integrated program
of training for prisoners, prison personnel and medical staff is also needed to improve the level of health
condition in prisons.
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Background
Hepatitis C virus (HCV) is one of the major public health
problems both in developed and developing countries,
leading to acute and chronic hepatitis [1]. It is estimated
that 71 million people in the world are suffering from
chronic HCV, and about 399,000 people die each year due
to cirrhosis and liver cancer [2]. The prevalence of HCV
has been computed to be approximately 0.6% in the
general population [3] and 0.5% among blood donors in
Iran [4].
Prison represents a high-risk environment for prisoners,
in that it is characterized by risky behaviors such as inject-
ing drug use (IDU), tattooing, unprotected sexual inter-
courses, or sharing syringes. For example, IDU represents
a major risk factor, with 52% of 11.7 million people inject-
ing drugs worldwide living with HCV [5]. Furthermore,
inadequate access to preventive interventions and diag-
nostic measures increases the risk of transmitting infec-
tions. HCV, like other pathogens, such as hepatitis B virus
(HBV) and human immunodeficiency virus (HIV), is
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transmitted through blood [6, 7]. HCV infection repre-
sents the main cause of liver cancer and can affect the out-
come of liver transplantation [8, 9]. Liver disease is a
major cause of death among inmates and has recently sur-
passed HIV. Compared to other subjects, prisoners are
more likely to develop HCV and to die of its complica-
tions [10–12].
According to the latest data available from the “Global
State of Harm Reduction” report and to a comprehen-
sive review of the global disease burden in prisoners, it
has been estimated that approximately 15.1% of 10.2
million people incarcerated at any given time are living
with HCV [5, 13]. More in detail, several studies have
been conducted to determine the prevalence of HCV
worldwide, reporting different findings. For example, 22.
7% of prisoners in Spain [14], 6.9% in Sri Lanka [15], 17.
7% in Turkey [16], 2.4% in Brazil [17], and 10.1% in the
USA [18] have been found to suffer from HCV infection.
Precise epidemiological figures related HCV preva-
lence are fundamental in the health sector for policy-
and decision-makers in each country to inform health
policies in an evidence-based way [19]. In recent years,
research has been conducted to determine the preva-
lence of HCV in Iran in order to estimate HCV infection
among prisoners. The knowledge of the epidemiology of
HCV among Iranian prisoners can effectively guide the
design and implementation of ad hoc harm reduction
programs. The aim of this study was to quantitatively
evaluate the prevalence of HCV among Iranian prisoners
conducting a systematic review and meta-analysis.
Methods
A protocol for the current systematic review and meta-
analysis was devised in accordance with the “Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses” (PRISMA) guidelines [20] and prospectively
registered in the PROSPERO database (identification ID:
CRD42018082336).
Two authors independently searched for articles related
to HCV infection among Iranian prisoners, mining schol-
arly databases such as Embase, PubMed/MEDLINE, ISI/
Web of Sciences, the Cochrane library, Scopus, CINAHL,
and PsycINFO. Iranian bibliographic thesauri were
searched as well (namely, Barakatns, MagIran, and SID),
with no language restrictions or time filter (searches per-
formed from inception until December 2017). The follow-
ing strategy was used: (“Prevalence” OR” Epidemiology”
OR “Frequency”) AND (“Hepatitis C virus” OR “HCV”
OR “Hepatitis “OR “Viral hepatitis”) AND (“Prison” OR
“Prisoner” OR “Inmates” OR “Jails” OR “Incarceration
“OR “Pre-trial detention” OR “Juvenile detention facil-
ities”) AND “Iran.” The reference list of each potentially
eligible study was also reviewed and hand-searched for in-
creasing the chance of getting relevant investigations.
Inclusion criteria
The inclusion criteria were as follows: (i) studies investi-
gating the prevalence of HCV among Iranian prisoners;
(ii) studies providing clear data and the possibility of
calculating the prevalence; (iii) studies designed as ob-
servational studies (that is to say, a variety of designs
were considered eligible including cross-sectional, case-
control, prospective, or retrospective investigations); (iv)
studies written in Persian and English; (v) studies that
used validated diagnostic tests such as enzyme-linked
immunosorbent assay (ELISA), polymerase-chain reac-
tion (PCR), and recombinant immunoblot assay (RIBA);
and (vi) studies that reported serological HCV data.
Exclusion criteria
Exclusion criteria were as follows (i) studies not con-
ducted among Iranian prisoners; (ii) studies not report-
ing sufficient data to estimate the prevalence rate; (iii)
studies designed as editorials, letters to editor, commen-
taries, expert opinions, case-series, case-reports, reviews,
or conference abstracts; and (iv) studies reporting over-
lapping/updated data.
Quality assessment
The Newcastle Ottawa Scale (NOS) was used to assess
the quality of the studies included. Based on the scores,
studies were classified into three categories, namely,
studies characterized by high risk (score in the range 1–
3), moderate risk (score in the range 4–6), and low risk
(score in the range 7–9).
Data extraction
Two authors independently extracted relevant informa-
tion from the articles, including the surname of the first
author, the location of the study, the year of publication,
the sample size, the mean age of the participants, the
diagnostic test used for HCV screening, the reported
prevalence, the number of people living with HCV, and
the duration of imprisonment.
Statistical analysis
HCV prevalence with its 95% confidence interval (CI) was
estimated using the DerSimonian-Laird random-effects
model [21] with Freeman-Tukey double arcsine trans-
formation [22]. To quantitatively assess heterogeneity
among articles, I2 test was used [23]. In case of statistically
significant heterogeneity, in order to investigate its
possible sources, meta-regression analyses were performed
based on the year of publication, sample size, and the
duration of the imprisonment. Furthermore, sensitivity
analyses were performed to ensure stability of the findings.
Egger’s regression test was used to evaluate publication
bias [24]. Based on sample size, quality of studies, and
length of conviction, subgroup analyses were conducted.
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Figures with p value < 0.05 were considered statistically
significant. Data were analyzed using STATAVer.14 (Stata
Corp, College Station, TX, USA).
Results
We identified an initial list of 273 articles, which re-
sulted in 184 items after deleting 89 duplicates. By
reviewing the title and/or abstract of these 184 articles,
145 unrelated articles were discarded. The full texts of
39 articles were reviewed, and finally 17 articles were se-
lected based on inclusion and exclusion criteria. Figure 1
shows the process of searching and selecting studies.
In the current systematic review and meta-analysis,
18,693 prisoners were tested. Studies were published
between 2004 and 2016. The sample size was between
101 and 8630. All studies used an ELISA diagnostic test
for the evaluation of HCV antibodies. Concerning the
quality of the studies, one study was found to be at high
risk, six at moderate risk, and ten at low risk. Table 1
shows the main characteristics of the studies included.
Based on the random-effects model, the prevalence of
HCV among Iranian prisoners was 28% (CI 95% 21–36)
with heterogeneity of I2 = 99.3% (p = 0.00), as shown in
Fig. 2.
To ensure the stability of the results, the sensitivity
analysis was performed in order to examine the impact
of each study on the overall prevalence. Before and after
this analysis, the overall prevalence did not change and
confirmed the stability of the findings (Fig. 3).
Subgroup analysis was performed based on variables
such as quality, sample size, and length of conviction.
Table 2 shows the results.
To evaluate possible heterogeneity sources among
studies, meta-regression analyses were carried out based
on the year of publication, sample size, and duration of
imprisonment. Table 3 shows the results. The prevalence
was borderline significant based both on the duration of
conviction (p = 0.073) and the year of study publication
(p = 0.074).
Various risk factors for HCV among Iranian pris-
oners have been reported including history of trad-
itional phlebotomy, blood transfusions, tattooing,
razor sharing, surgery, history of dental operations,
sharing a syringe/needle, drug use, unprotected sex,
sexually transmitted infections, alcohol consumption,
Fig. 1 The process of search and selection of studies
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Table 1 The characteristics of studies included
First author Publication year Province Age (mean ± SD) Sample size Prevalence (%) Diagnostic test Quality of studies
Rowhani-Rahbar 2004 Razavi Khorasan 32.8 ± 8.9 110 59.4 ELISA High
Mohammad
Alizadeh
2005 Hamedan NA 427 30 ELISA Medium
Zakizadeh 2006 Mazandaran NA 312 30.80 ELISA High
Mohtasham Amiri 2007 Guilan 34.7 ± 8.9 460 45.40 ELISA Medium
Pourahmad 2007 3 provinces NA 1431 34.70 ELISA High
Azarkar 2007 South Khorasan 34.1 ± 11.7 400 7.80 ELISA High
Asgari 2008 10 provinces NA 8630 37.85 ELISA High
Zakizad M 2009 Mazandaran NA 312 30.80 ELISA Medium
Tajbakhsh 2009 Chaharmahal and
Bakhtiari
25.8 600 12.66 ELISA Low
Davoodian 2009 Hormozgan 35.4 ± 8.4 249 64.80 ELISA High
Azarkar 2010 South Khorasan 34.7 ± 12 358 8.10 ELISA High
Kassaian 2012 Isfahan 32.6 943 41.60 ELISA Medium
Naghili 2012 East Azerbaijan 31.3 ± 10 192 29 ELISA High
Nokhodian 2012 Isfahan 34.54 ± 11.2 163 7.40 ELISA High
Ziaee 2014 South Khorasan 34.7 ± 11.4 881 7.70 ELISA Medium
Alasvand 2015 6 Providences 37 ± 13 2120 12.90 ELISA Medium
Khajedaluee 2016 Razavi Khorasan 53.37 ± 54.9 1114 24.50 ELISA High
Fig. 2 The overall prevalence of HCV in prisoners Iranian based on the random-effects model
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piercings, IDU, history of cupping, dialysis, and abor-
tion. According to available data, we calculated the
odds ratio (OR) for some of these factors (Table 4).
Egger’s regression test showed that there was no pub-
lication bias for the selected studies (p = 0.94) (Fig. 4).
Discussion
To the best of our knowledge, this study was the first
and most comprehensive systematic review and meta-
analysis that examined the prevalence of HCV among
Iranian prisoners. Comprehensive search, the use of a
checklist to assess the risk of studies, meta-regressions,
sensitivity analysis, and publication bias assessment are
among the strengths of this study.
HCV infection among inmates is a very serious prob-
lem that healthcare professionals in each country have
to face. Given that there are about 10 million prisoners
around the world [25], attention to HCV prevention
should be a public health priority in prisons in all de-
veloped and developing countries [26].
The findings of this study showed that the prevalence
of HCV among Iranian prisoners was 28% (CI 95% 21–
36). This rate is higher than the prevalence in the gen-
eral population [3]—0.6% (CI 95% 0.4–0.8%)—and blood
donors in Iran [4]—0.5% (CI 95% 0.4–0.6%).
Compared to international studies, this rate is
higher than the prevalence reported among prisoners
in Italy (22.4%) [27], in Brazil (2.4%) [17], and in
France (4.8%) [28], and lower than the prevalence re-
ported in California (34.3%) [29] and in Indonesia
(34.1%) [30].
The causes of the difference in the prevalence among
the studies carried out in different countries can be the
type of prison population surveyed on the basis of sig-
nificant risk factors such as IDU or the history of impris-
onment and the conduct of high-risk sexual behaviors or
other high-risk behaviors.
Prison health conditions vary in different parts of the
world, and in many countries, there is still no definite
policy to further improve the health of prisoners. On
the other hand, it seems that screening conditions are
not adequately provided for many of them at the time
of imprisonment. The rules governing the legal system
of the countries make it possible to create complex
constraints for screening HCV. Sometimes, it is, in-
deed, difficult to reach a balance between ensuring
adequate health standards and public safety, for ex-
ample guaranteeing to prisoners continuity of health-
care and access to healthcare facilities (such as
screening centers), before and during the transfer to
custodial settings. On the other hand, there are also
Fig. 3 The sensitivity analysis of the prevalence of HCV in prisoners Iranian based on the random-effect model
Table 2 The results of subgroup analysis
Items Prevalence 95% CI I2 (%) P
Quality of studies
High 13% (10–15) – –
Intermediate 28% (16–40) 99.1 0.00
Low 30% (20–40) 99.2 0.00
Sample size
≤ 400 29% (16–43) 98.6 0.00
> 400 27% (18–37) 99.5 0.00
Prisoner type
Prisoners who inject drugs 53% (42–64) 94.6 0.00
Prisoners who make use of drugs 25% (11–38) 97.5 0.00
General (non-risk) 19% (10–29) 99.5 0.00
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financial problems in many sectors, such as the health
and legal systems of the countries, which have led to
the unfeasibility of screening all inmates [5]. Ensuring
timely diagnostic tests for HCV would be, indeed, too
much expensive. Even though numerous studies have
assessed the cost-effectiveness of screening prisoners
for HCV, there is a dearth of information specifically
concerning Iran. Furthermore, despite the fact that
HCV is very common in prisoners and threatens their
health status and conditions, there is still no screening
program in Iran as well as in many countries [27]. Over
the past years, policies have been developed in Iran to
improve the health situation in Iran’s prisons, but these
efforts have not been sufficient and there is still a huge
gap to be filled [31].
The findings of this study showed that the highest
prevalence (53%) was among prisoners who inject drugs.
This finding is in line with other published investiga-
tions, including a Scottish study [32]. In a meta-analysis
study that evaluates HCV in prisoners, the prevalence of
IDU was estimated to be 64% [10]. The most important
risk factor associated with HCV is, indeed, IDU, and this
is a common danger in all prisons in the world. How-
ever, because of the lack of the implementation of
proper harm reduction policies, it still remains a major
problem for prisoners [33].
Studies show that IDU-related practices in Iran are
on the rise [34]. Prisoners who inject drugs are more
susceptible to infections such as HCV, HBV, and HIV
than others [35]. Unfortunately, in recent decades, drug
use has increased in Iran, and the pattern of drug use
has changed, with an increasing trend in IDU [36]. In
our findings, the OR for HCV for prisoners who inject
drugs compared to other prisoners was 3.54. Findings
from various studies indicate that prisoners are poten-
tially susceptible to HCV [17, 37, 38]. The OR in pris-
oners who had a history of sharing syringes/needles
was 4.06 in comparison with other people. The lack of
access to needle and syringe programs in prisons has
led to a very high incidence of HCV [39]. Officials
should identify prisoners who inject drugs to control
HCV infection at the very beginning of their arrival,
and provide them with sterile needles and syringes to
prevent the spread of infection to other prisoners. The
harm reduction-based training given to prisoners can
also have an effective role in reducing the infection. In
a study conducted in European countries, sterile syrin-
ges and needles were provided to prisoners, and they
also received adequate training. Results showed that the
use of syringes by other prisoners was reduced and no
new cases HCV were reported [40].
Tattooing in prisons is another major health con-
cern, due to the use of non-sterile devices leading to
transmission of infections such as HCV, HBV, and
HIV. In a meta-analysis study published in 2017, tat-
toos are considered as one of the most important risk
factors for HCV transmission [41]. In the current
study, those with a history of tattooing had a 2.59
higher risk than those without a history of tattooing.
Two cohort studies in Australia have reported a
significant relationship between tattooing and HCV
infection [42, 43]. Prison authorities should provide
harm reduction interventions for prisoners to help re-
duce any harms associated with these activities. A
study conducted in seven European countries refers
to the role of harm reduction programs and the im-
provement of health of prison population and the re-
duction of HCV [44].
The results of meta-regression analyses showed that
there is a borderline significant relationship between
the prevalence rate of HCV among Iranian prisoners
and the year of studies publication. Since 2005, health
policy- and decision-makers in the country have de-
cided to formally adopt a harm reduction policy.
Table 3 The results of meta-regression
Variables Coef SE P value Adjusted R2 (%)
Publication year − 0.022 0.011 0.074 14.30
Sample size 6.38 0.000 0.78 − 6.31
Duration of incarceration (years) 0.108 0.049 0.073 36.01
Table 4 Odds ratio (OR) for HCV-related risk factors
Items Number of studies Odds ratio (95% CI) I2 (%) P
Injection of drugs 8 3.54 (2.28–5.49) 88.6 0.00
Tattooing 6 2.59 (1.74–3.86) 81.7 0.00
Having shared a syringe/needle 4 4.06 (0.70–23.51) 95.4 0.00
History of transfusion 4 1.61 (0.91–2.86) 55 0.00
Use of drugs 3 1.16 (0.38–3.54) 94.3 0.00
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Within this policy, prisoners who make use of drugs
such as opioids can be legally treated with methadone.
A strategy for making available sterile syringes and nee-
dles to prisoners who inject drugs was also considered
[36]. However, despite the implementation of this pol-
icy, HCV infection among Iranian prisoners remains a
challenge [45].
According to the findings of meta-regressions, the
prevalence of HCV among Iranian prisoners has in-
creased with time and length of conviction. The find-
ings of a study carried out in Brazil seem to confirm
this finding [17]. Prisoners are familiar with high-risk
behaviors in prison over time, and in many cases,
they may experience them. The results of a study in
Ireland show that at least 21% of prisoners have expe-
rienced the first injection in jails [46].
However, this study has some limitations that
should be mentioned: the major drawback is given by
the presence of statistically significant heterogeneity
among studies [47]. Furthermore, for many provinces
of Iran, there is a dearth of information as no studies
have been conducted. Moreover, data available did
not allow comparisons to be performed based on
gender.
Conclusions
In conclusion, health policy- and decision-makers in
Iran need good evidence to improve public health sta-
tus in prisons. The findings of our study showed that
the prevalence of HCV among Iranian prisoners was
28%. This prevalence is dramatically high. Managing
this issue in Iran’s prisons requires careful attention
to the availability of health facilities and instruments,
such as screening, and harm reduction policies, such
as making needle and syringe programs available to
prisoners. An integrated program of training for pris-
oners, prison personnel, and medical staff is also
needed to improve the level of health condition in
prisons.
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